The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge.

Learn more about your ad choices. Visit megaphone.fm/adchoices

B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions

Learn more about your ad choices. Visit megaphone.fm/adchoices

Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.

Learn more about your ad choices. Visit megaphone.fm/adchoices

A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate.

Learn more about your ad choices. Visit megaphone.fm/adchoices